Delving into the Latest Updates on LanthioPep BV with Synapse

概览

关联

1

项与 LanthioPep BV 相关的药物

MOR-107

靶点

AT2R

作用机制

AT2R激动剂

在研机构-

原研机构

MorphoSys AG

在研适应症-

非在研适应症

糖尿病肾病

最高研发阶段终止

首次获批国家/地区-

首次获批日期-

1

项与 LanthioPep BV 相关的临床试验

NCT03067363

/ Terminated临床1期

Assessment of Safety, Tolerability and Pharmacokinetics of Single Ascending Subcutaneous Doses of MOR107 in Healthy Male Subjects and Pharmacodynamics in Healthy Male Subjects on a Low Sodium Diet

This is the first in human study of MOR107. It is a 2 part, single centre, double-blind, randomised, placebo-controlled study in healthy male subjects. Part 1 is a single ascending dose study, and Part 2 is a parallel group, dose range finding study in healthy male subjects on a low sodium diet.

开始日期2017-02-16

申办/合作机构

LanthioPep BV

[+1]

100 项与 LanthioPep BV 相关的临床结果

登录后查看更多信息

0 项与 LanthioPep BV 相关的专利（医药）

登录后查看更多信息

100 项与 LanthioPep BV 相关的药物交易

登录后查看更多信息

100 项与 LanthioPep BV 相关的转化医学

登录后查看更多信息